Why the study?
Do NOACs compared to enoxaparin affect the incidence of post-operative arterial thrombosis in patients undergoing total hip or knee arthroplasty?
Do NOACs compared to enoxaparin affect the incidence of post-operative arterial thrombosis in patients undergoing total hip or knee arthroplasty?
NOACs do not increase the risk of post-operative arterial thrombosis compared to enoxaparin when used for VTE prophylaxis after total hip or knee arthroplasty.
Answers are grounded in this paper and cite their sources.
Supports NOAC use for post-arthroplasty VTE prophylaxis without arterial thrombosis concern; confirms comparable safety to enoxaparin.
The incidence of post-operative arterial thrombosis (AT) (acute myocardial infarction [AMI] and ischaemic stroke) is increased in patients undergoing total hip replacement (THR) or total knee replacement (TKR). We compared the incidence of post-operative AT in non-vitamin K antagonist oral anticoagulants (NOACs)-treated and enoxaparin-treated patients, performing a systematic review of phase III randomised controlled trials (RCTs) of venous thromboembolism (VTE) prophylaxis in THR and TKR. Studies were identified by electronic search of MEDLINE and EMBASE database until July 2014. Differences between NOACs and enoxaparin groups in the efficacy and safety outcomes were expressed as odds ratios (ORs) with pertinent 95 % confidence intervals (95 % CI). Statistical heterogeneity was assessed with the I² statistic. Eleven phase III RCTs for a total of 31,319 patients were included. Patients underwent TKR in six studies and THR in five studies. The NOACs under study were dabigatran (four studies), apixaban (three studies) and rivaroxaban (four studies). AT occurred in 0.23 % of patients on NOACs and in 0.27 % of patients on enoxaparin: the OR at fixed-effect model was 0.86 (95 % CI 0.53-1.40; I² 11 %). No differences in AT incidence among the three NOACs were observed. The incidence of major and clinically relevant bleeding was similar in NOACs and enoxaparin groups (OR 1.03, 95 % CI 0.92-1.15; I² 38 %). In conclusion, in RCTs of pharmacological VTE prophylaxis in patients undergoing THR or TKR, there was no difference in the incidence of post-operative AT among patients treated with NOACs, compared to those treated with enoxaparin.
No takes yet. Share an insight, caveat, or question.
A 2015 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: